Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections

被引:21
|
作者
Chalmers, James D. [1 ]
van Ingen, Jakko [2 ]
van der Laan, Roald [3 ]
Herrmann, Jean-Louis [4 ,5 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee, Scotland
[2] Radboud Univ Nijmegen, Radboudumc Ctr Infect Dis, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
[3] Insmed BV, Utrecht, Netherlands
[4] Univ Paris Saclay, UVSQ, Infect & Inflammat, INSERM, Montigny Le Bretonneux, France
[5] Grp Hosp Univ Paris Saclay, Hop Raymond Poincare, AP HP, Garches, France
来源
EUROPEAN RESPIRATORY REVIEW | 2021年 / 30卷 / 161期
关键词
PSEUDOMONAS-AERUGINOSA INFECTION; MECHANICALLY VENTILATED PATIENTS; TIME-KILL KINETICS; AVIUM COMPLEX; CYSTIC-FIBROSIS; CELL-WALL; AMIKACIN CONCENTRATIONS; ENCAPSULATED-AMIKACIN; RESISTANCE MECHANISMS; ABSCESSUS COMPLEX;
D O I
10.1183/16000617.0010-2021
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Chronic Pulmonary Aspergillosis Following Nontuberculous Mycobacterial Infections: An Emerging Disease
    Phoompoung, Pakpoom
    Chayakulkeeree, Methee
    JOURNAL OF FUNGI, 2020, 6 (04) : 1 - 10
  • [2] The lung microbiota in nontuberculous mycobacterial pulmonary disease
    Kim, Bo-Guen
    Kang, Noeul
    Kim, Su-Young
    Kim, Dae Hun
    Kim, Hojoong
    Kwon, O. Jung
    Huh, Hee Jae
    Lee, Nam Yong
    Jhun, Byung Woo
    PLOS ONE, 2023, 18 (05):
  • [3] THE LUNG MICROBIOME IN NONTUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE
    Kumar, K.
    Cuthbertson, L.
    Ellis, H. C.
    Churchward, C.
    Loebinger, M. R.
    Moffatt, M. F.
    Cookson, W. O. C.
    THORAX, 2022, 77 : A36 - A36
  • [4] The lung microbiota in nontuberculous mycobacterial pulmonary disease
    Kim, Bo-Guen
    Kang, Noeul
    Kim, Su-Young
    Kim, Dae Hun
    Kim, Hojoong
    Kwon, O. Jung
    Huh, Hee Jae
    Lee, Nam Yong
    Kim, Jhingook
    Jhun, Byung Woo
    RESPIROLOGY, 2023, 28 : 7 - 7
  • [5] Nontuberculous mycobacterial pulmonary infections
    Johnson, Margaret M.
    Odell, John A.
    JOURNAL OF THORACIC DISEASE, 2014, 6 (03) : 210 - 220
  • [6] Nontuberculous mycobacterial infections of the lung
    Irene S. Kourbeti
    Melanie J. Maslow
    Current Infectious Disease Reports, 2000, 2 (3) : 193 - 200
  • [7] Lung disease due to nontuberculous mycobacterial infections - Preface
    Catanzaro, A
    Daley, CL
    CLINICS IN CHEST MEDICINE, 2002, 23 (03) : XI - XII
  • [8] Randomized Trial of Liposomal Amikacin for Inhlation in Nontuberculous Mycobacterial Lung Disease
    Olivier, Kenneth N.
    Griffith, David E.
    Eagle, Gina
    McGinnis, John P., II
    Micioni, Liza
    Liu, Keith
    Daley, Charles L.
    Winthrop, Kevin L.
    Ruoss, Stephen
    Addrizzo-Harris, Doreen J.
    Flume, Patrick A.
    Dorgan, Daniel
    Salathe, Matthias
    Brown-Elliott, Barbara A.
    Gupta, Renu
    Wallace, Richard J., Jr.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195 (06) : 814 - 823
  • [9] Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease
    Marras, Theodore K.
    Campitelli, Michael A.
    Kwong, Jeffrey C.
    Lu, Hong
    Brode, Sarah K.
    Marchand-Austin, Alex
    Gershon, Andrea S.
    Jamieson, Frances B.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48 (03) : 928 - 931
  • [10] Nontuberculous mycobacterial infection in chronic obstructive pulmonary disease
    Okamori, Satoshi
    Tanaka, Eisaku
    Hamao, Nobuyoshi
    Yasuda, Yuto
    Inao, Takashi
    Morimoto, Chie
    Yasuda, Ikkou
    Kaji, Yusuke
    Yasuda, Takehiro
    Hashimoto, Seishu
    Hajiro, Takashi
    Taguchi, Yoshio
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46